Check out these recent opioid-related releases:
RxAwareness Campaign
With the tagline, “It only takes a little to lose a lot,” the Rx Awareness campaign tells the real stories of people whose lives were torn apart by prescription opioids. The goal of the campaign is to increase awareness that prescription opioids can be addictive and dangerous. Please help CDC spread the word about the campaign by using this social media kit for more sharable resources.
With the tagline, “It only takes a little to lose a lot,” the Rx Awareness campaign tells the real stories of people whose lives were torn apart by prescription opioids. The goal of the campaign is to increase awareness that prescription opioids can be addictive and dangerous. Please help CDC spread the word about the campaign by using this social media kit for more sharable resources.
- CDC Web Feature: Rx Awareness: Impact of an Epidemic
Read more about how we can work together to share stories of Americans whose lives have been impacted by the opioid epidemic.
New Opioid Overdose Materials for Patients
CDC released several patient-centered materials aimed at educating people about opioid use for acute pain. All materials are free and available for download.
CDC released several patient-centered materials aimed at educating people about opioid use for acute pain. All materials are free and available for download.
- What You Need to Know outlines the differences in acute and chronic pain and what you need to know when prescribed opioids for acute pain management.
- Get the Facts Infographic highlights important information about acute pain management for common conditions and injuries.
- Know the Signs. Save a Life is a resource that identifies factors that can increase the risk of overdose and the steps to take to prevent overdose related death.
New Provider Training Module: Communicating with Patients
Through this training, participants will be able to describe effective communication strategies that promote healthy dialogue with patients regarding benefits and harms of opioids. This and all future trainings will be available for free continuing education credit and can be found on our Training for Providers web page. This training series helps healthcare providers gain a deeper understanding of theCDC Guideline for Prescribing Opioids for Chronic Pain.
Through this training, participants will be able to describe effective communication strategies that promote healthy dialogue with patients regarding benefits and harms of opioids. This and all future trainings will be available for free continuing education credit and can be found on our Training for Providers web page. This training series helps healthcare providers gain a deeper understanding of theCDC Guideline for Prescribing Opioids for Chronic Pain.
HuffPost Blog: Keeping Patients Safe While Treating Pain
Professionals work every day to ensure safe opioid prescribing. CDC Injury Center’s Director, Dr. Deb Houry interviewed professionals about managing priorities, preventing opioid overdose, and keeping patients safe while treating pain.
Professionals work every day to ensure safe opioid prescribing. CDC Injury Center’s Director, Dr. Deb Houry interviewed professionals about managing priorities, preventing opioid overdose, and keeping patients safe while treating pain.
Articles
- Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700 — 10 States, July–December 2016 (MMWR)
- Illicitly-manufactured fentanyl is a key factor driving opioid overdose deaths. Fentanyl analogs are substances that are structurally or pharmacologically similar to fentanyl and are increasingly contributing to a complex illicit opioid market, especially with extensive mixing or co-use with other illicit drugs such as heroin and cocaine. This report analyzed fatal opioid overdose data from 10 states participating in the Enhanced State Opioid Overdose Surveillance (ESOOS) program.
- Illicit Drug Use, Illicit Drug Use Disorders, and Drug Overdose Deaths in Metropolitan and Nonmetropolitan Areas — United States (MMWR)
- Drug overdose death rates are now higher in nonmetropolitan (rural) areas than metropolitan (urban) areas. This report analyzed trends in illicit drug use, illicit drug use disorders, and drug overdose deaths in urban and rural areas. Understanding differences in illicit drug use, illicit drug use disorders, and drug overdose deaths in urban and rural areas can help public health professionals to identify, monitor, and prioritize responses.
- Underlying Factors in Drug Overdose Deaths (JAMA)
- Preliminary data from CDC indicate that drug overdoses increased between 2015 and 2016---by more than 20%. This increase is being driven by overdoses related to synthetic opioids (i.e., illicit fentanyl). Since 2010, overdose deaths involving heroin and synthetic opioids including fentanyl have increased more than 200%. These findings underscore the need to continue efforts to address and prevent this public health problem.
- Contribution of Opioid-Involved Poisoning to the Change in Life Expectancy in the United States, 2000-2015 (JAMA)
- Life expectancy in the United States is lower than most high income countries, and this gap is expected to increase. The average life expectancy has dropped by 0.1 years in 2015, compared to 2014. This study examines the impact of drug (particularly those involving opioids) and alcohol poisoning deaths on U.S. life expectancy from 2000-2015, comparing them with the 12 leading causes of death in 2015.
Preparing for 2018 RxSummit
The National Rx Drug Abuse & Heroin Summit is the annual gathering for stakeholders to discuss what is working in prevention and treatment. Be part of the international discussion on addressing the opioid crisis by attending the 2018 National Rx Drug Abuse & Heroin Summit in Atlanta. Registration is now open.
The National Rx Drug Abuse & Heroin Summit is the annual gathering for stakeholders to discuss what is working in prevention and treatment. Be part of the international discussion on addressing the opioid crisis by attending the 2018 National Rx Drug Abuse & Heroin Summit in Atlanta. Registration is now open.
No hay comentarios:
Publicar un comentario